Consensus HPV Vaccine Nucleic Acids for Broad Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines face challenges in inducing effective immune responses, particularly in larger animals and humans, with DNA vaccines showing decreased immunogenicity and limited efficacy against HPV subtypes associated with cervical and other cancers.
Innovation Solution
Development of nucleic acid molecules encoding consensus sequences for HPV antigens, such as HPV 6, 11, 33, and 58, combined with codon optimization, RNA optimization, and immunoglobulin leader sequences, delivered via DNA vaccines, recombinant vaccines, or live attenuated vaccines to enhance cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional DNA vaccines are used, then safety and stability are improved, but immunogenicity decreases in larger animals and humans
Solution Approach 1:
The patent applies parameter changes by optimizing codon usage to match host cell preferences, adding immunoglobulin leader sequences to enhance protein expression and secretion, and modifying RNA secondary structures to improve translation efficiency. These parameter optimizations transform the DNA vaccine construct to achieve both safety and high immunogenicity in humans
Solution Approach 2:
The patent creates a composite vaccine construct that integrates multiple functional elements: optimized coding sequences, immunoglobulin leader sequences, and adjuvant components. This composite structure combines the safety of DNA vaccines with enhanced immunogenicity through multiple synergistic elements working together
2Adaptability or versatility
If consensus sequence DNA vaccines are used, then breadth of cellular immune response is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the HPV antigen into conserved epitopic regions that are common across multiple serotypes. By focusing on these conserved segments rather than entire viral proteins, the vaccine achieves broad coverage while simplifying the manufacturing process through targeted expression of specific immunogenic regions
3Adaptability or versatility
If multiple HPV serotypes are targeted, then serotype coverage is improved, but vaccine complexity increases
Solution Approach 1:
The patent designs a universal DNA vaccine construct that can target multiple HPV serotypes simultaneously through consensus sequence design. The single optimized plasmid expresses antigens that elicit cross-protective immune responses against multiple serotypes, replacing the need for separate vaccines for each serotype and reducing overall vaccine program complexity
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3B
AI summary
Anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV 6, HPV 11, HPV 33 and HPV58 E6 and E7. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.